The DNAJA2 Knockout HT29 Polyclonal Cells represent a CRISPR/Cas9-edited polyclonal knockout cell population engineered to disrupt the DNAJA2 gene in the human HT29 colon epithelial cell line. This mixed-population model provides a physiologically relevant tool for studying loss-of-function effects of the Hsp40 co-chaperone DNAJA2 without clonal selection, enabling researchers to assess heterogeneous cellular responses in a colorectal cancer background. The polyclonal format maintains genetic diversity while targeting DNAJA2, making it suitable for pooled functional genomics, drug screening, and proteostasis network analysis.
HT29 is an adherent epithelial cell line originally derived from a primary colorectal adenocarcinoma of a 44-year-old female. It serves as a well-established model for intestinal epithelial biology and colon cancer research, retaining key oncogenic mutations and signaling pathway activation that drive tumor cell proliferation and survival. HT29 cells exhibit glandular differentiation features under appropriate conditions and are widely employed to study colorectal cancer pathogenesis, drug resistance mechanisms, and epithelial barrier function.
DNAJA2 encodes a J-domain co-chaperone that stimulates the ATPase activity of Hsp70 (HSPA1A/HSPA1B), accelerating client protein binding and folding. It forms complexes with Hsp90, the BAG family co-chaperones (e.g., BAG3), HOP, HIP, and the E3 ubiquitin ligase CHIP to orchestrate protein triage between folding and degradation. DNAJA2 is transcriptionally regulated by heat shock factors (HSF) and ER stress sensors (ATF6, XBP1), and its activity modulates downstream Hsp70 clients including mutant p53, signaling kinases, and apoptotic regulators such as caspases. Knockout of DNAJA2 disrupts this chaperone cycle, leading to accumulation of misfolded proteins, altered MAPK and Akt signal transduction, and impaired proteasomal degradation of polyubiquitinated substrates.
In the context of HT29 colorectal adenocarcinoma cells, DNAJA2 knockout compromises the chaperone network that cancer cells exploit to manage oncogenic proteotoxic stress. HT29 cells express mutant p53 and exhibit constitutive MAPK pathway activation, both of which rely on Hsp70-mediated stabilization. Loss of DNAJA2 therefore sensitizes these cells to protein quality control defects and may expose vulnerabilities to proteasome inhibitors or Hsp90-targeted therapies. This model allows dissection of co-chaperone-specific functions in colorectal cancer cell survival, protein aggregation dynamics, and therapy resistance.
Typical applications include investigation of chaperone-mediated protein quality control via western blotting for Hsp70 clients (e.g., ubiquitin, p53), RT-qPCR profiling of stress response genes, and RNA-seq analysis of proteostasis networks. Functional assays such as flow cytometry with Annexin V staining quantify apoptosis, while co-immunoprecipitation of Hsp70 complexes reveals altered interaction landscapes. Drug sensitivity profiling with proteasome or Hsp90 inhibitors and migration/invasion assays further elucidate DNAJA2 roles in therapeutic response and metastatic behavior. For further information, please contact Ascent Research.
